Inventor · disambiguated record
Norifumi Sato
Also filed as: SATO NORIFUMI
6 granted patents·7 pending applications·7 citations·filing 2005–2024
75Inventor score
Top patents by PatentIndex Score
13 records- 0184US2024148699A1Oxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0277US2022265613A1Oxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 0376USRE46792EOxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2006·Granted Apr 17, 2018·2 cites·16 claims
- 0472US7834002B24-amino-5-cyanopyrimidine derivativesOTSUKA PHARMA CO LTD·Filed 2005·Granted Nov 16, 2010·2 cites·11 claims
- 0571US8637559B2Oxazole compound and pharmaceutical compositionOKADA MINORU·Filed 2006·Granted Jan 28, 2014·1 cites·10 claims
- 0670US7989446B24-amino 5-cyanopyrimidine derivativesOTSUKA PHARMA CO LTD·Filed 2010·Granted Aug 2, 2011·2 cites·5 claims
- 0766US2020078340A1Oxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2019·Application pending·0 cites
- 0864US2019070151A1Oxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2018·Application pending·0 cites
- 0960US2017216260A1Oxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2017·Application pending·0 cites
- 1060US2014100226A1Oxazole compound and pharmaceutical compositionOTSUKA PHARMA CO LTD·Filed 2013·Application pending·0 cites
- 1156US2014315801A1Methods of treatment of cell proliferative and/or ophthalmic diseases, disorders and conditions using inhibitors of protein tyrosine kinase activityMETHYLGENE INC·Filed 2014·Application pending·0 cites
- 1243US8906852B2Inhibitors of protein tyrosine kinase activityRAEPPEL STÉPHANE·Filed 2011·Granted Dec 9, 2014·0 cites·17 claims
- 1333US9708292B2Cyanopyrimidine derivativeSATO NORIFUMI·Filed 2010·Granted Jul 18, 2017·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Norifumi Sato files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →